193 related articles for article (PubMed ID: 28712622)
41. Analysis of Medicine Prices in New Zealand and 16 European Countries.
Vogler S; Kilpatrick K; Babar ZU
Value Health; 2015 Jun; 18(4):484-92. PubMed ID: 26091603
[TBL] [Abstract][Full Text] [Related]
42. Convergence of decision rules for value-based pricing of new innovative drugs.
Gandjour A
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
[TBL] [Abstract][Full Text] [Related]
43. Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data.
Blome C; Augustin M; Metin H; Lohrberg D
Eur J Health Econ; 2017 Mar; 18(2):181-193. PubMed ID: 26837412
[TBL] [Abstract][Full Text] [Related]
44. [Mechanics and effects of European reference pricing for vaccines in Germany according to §130a Abs. 2 SGB V: an analysis using the example of influenza vaccines].
Barth J; Hammerschmidt T; Vollmar J; Bierbaum M; Schöffski O
Gesundheitswesen; 2014 Apr; 76(4):e7-e13. PubMed ID: 24081570
[TBL] [Abstract][Full Text] [Related]
45. [Actual medical care situation and therapeutic needs in multiple sclerosis: Impact of the Pharmaceutical Market Restructuring Act (AMNOG)].
Bittner S; Meuth SG
Nervenarzt; 2016 Apr; 87(4):394-401. PubMed ID: 27023842
[TBL] [Abstract][Full Text] [Related]
46. Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations.
DiStefano MJ; Levy JF; Odouard IC; Anderson GF
Value Health; 2023 Nov; 26(11):1618-1624. PubMed ID: 37689264
[TBL] [Abstract][Full Text] [Related]
47. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
Pavenik N
Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
[TBL] [Abstract][Full Text] [Related]
48. Do WHO pharmaceutical pricing guidelines help low- and middle-income countries to price medicines rationally?
Kheirandish M
East Mediterr Health J; 2020 Apr; 26(4):372-373. PubMed ID: 32338354
[No Abstract] [Full Text] [Related]
49. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
50. Economic aspects of the new Spanish laws on pharmaceutical preparations.
Antoñanzas F; Oliva J; Pinillos M; Juàrez C
Eur J Health Econ; 2007 Sep; 8(3):297-300. PubMed ID: 17401592
[TBL] [Abstract][Full Text] [Related]
51. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
52. The impact of price-cap regulations on market entry by generic pharmaceutical firms.
Zhang W; Sun H; Guh D; Anis AH
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):231-238. PubMed ID: 27936981
[TBL] [Abstract][Full Text] [Related]
53. Fixed-dose combination and single active ingredient drugs: a comparative cost analysis.
Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):127-34. PubMed ID: 26174631
[TBL] [Abstract][Full Text] [Related]
54. Price-cap Regulation, Uncertainty and the Price Evolution of New Pharmaceuticals.
Shajarizadeh A; Hollis A
Health Econ; 2015 Aug; 24(8):966-77. PubMed ID: 24990225
[TBL] [Abstract][Full Text] [Related]
55. The Impact Of Price Regulation On The Availability Of New Drugs In Germany.
Stern AD; Pietrulla F; Herr A; Kesselheim AS; Sarpatwari A
Health Aff (Millwood); 2019 Jul; 38(7):1182-1187. PubMed ID: 31260362
[TBL] [Abstract][Full Text] [Related]
56. The impact of pricing and patent expiration on demand for pharmaceuticals: an examination of the use of broad-spectrum antimicrobials.
Kaier K
Health Econ Policy Law; 2013 Jan; 8(1):7-20. PubMed ID: 22947241
[TBL] [Abstract][Full Text] [Related]
57. Do generics offer significant savings to the UK National Health Service?
Kanavos P
Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
[TBL] [Abstract][Full Text] [Related]
58. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.
Vogler S; Vitry A; Babar ZU
Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089
[TBL] [Abstract][Full Text] [Related]
59. [Medical problems associated with the national reference pricing system in Hungary].
Kerpel-Fronius S
Orv Hetil; 2004 Apr; 145(17):913-8. PubMed ID: 15170969
[TBL] [Abstract][Full Text] [Related]
60. Assessing social preferences in reimbursement negotiations for new Pharmaceuticals in Oncology: an experimental design to analyse willingness to pay and willingness to accept.
Wettstein DJ; Boes S
BMC Health Serv Res; 2021 Mar; 21(1):234. PubMed ID: 33726735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
